

Emergent BioSolutions Inc.
Form 8-K
October 06, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 30, 2011

Emergent BioSolutions Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation)	001-33137 (Commission File Number)	14-1902018 (IRS Employer Identification No.)
---	--	--

2273 Research Boulevard, Suite 400, Rockville, Maryland (Address of Principal Executive Offices)	20850 (Zip Code)
---	---------------------

Registrant's telephone number, including area code: (301) 795-1800

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01. Entry into a Material Definitive Agreement.

Centers for Disease Control and Prevention Contract Modification

On September 30, 2011, Emergent BioDefense Operations Lansing LLC, a wholly owned subsidiary of Emergent BioSolutions Inc. (the “Company”), received a notice of award from the Centers for Disease Control and Prevention (“CDC”) to supply up to 44.75 million doses of BioThrax® (Anthrax Vaccine Adsorbed) (“BioThrax”) to the CDC over a five-year period. The maximum amount that could be paid to the Company under the award could be up to \$1.25 billion, subject to availability of funding. The period of performance under the award is from September 30, 2011 through September 29, 2016. Delivery of doses under the award is anticipated to commence in December of 2011, immediately following the completion of deliveries under the Company’s current supply contract with the CDC.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 6, 2011

EMERGENT BIOSOLUTIONS INC.

By:/s/Jay G. Reilly
Jay G. Reilly
General Counsel

